Novo Nordisk Shares Plunge on Insulin's FDA Failure

Feb. 11 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk shares have fallen the most in a decade as the company's new insulin drug Tresiba has failed to win FDA approval in the United States. She speaks on Bloomberg Television's "The Pulse."
Equity Valuations Lofty, Earnings Lousy: Morganlander
54:57 - Stifel Nicolaus' Chad Morganlander and Bloomberg's Michael Regan discuss the global selloff in stocks with Bloomberg's Pimm Fox on "Taking Stock." (Source: Bloomberg)
  • `Time Is of the Essence' for Greece to Reach Deal: Lew
  • A Penthouse Perspective on NYC Real Estate
  • Will the Comcast-Time Warner Cable Merger Ever Happen?